Gnao1 is a molecular switch that regulates the Rho signaling pathway in differentiating neurons.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 Jul 2024
Historique:
received: 29 03 2024
accepted: 19 07 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 24 7 2024
Statut: epublish

Résumé

GNAO1 encodes G protein subunit alpha O1 (Gαo). Pathogenic variations in GNAO1 cause developmental delay, intractable seizures, and progressive involuntary movements from early infancy. Because the functional role of GNAO1 in the developing brain remains unclear, therapeutic strategies are still unestablished for patients presenting with GNAO1-associated encephalopathy. We herein report that siRNA-mediated depletion of Gnao1 perturbs the expression of transcripts associated with Rho GTPase signaling in Neuro2a cells. Consistently, siRNA treatment hampered neurite outgrowth and extension. Growth cone formation was markedly disrupted in monolayer neurons differentiated from iPSCs from a patient with a pathogenic variant of Gαo (p.G203R). This variant disabled neuro-spherical assembly, acquisition of the organized structure, and polarized signals of phospho-MLC2 in cortical organoids from the patient's iPSCs. We confirmed that the Rho kinase inhibitor Y27632 restored these morphological phenotypes. Thus, Gαo determines the self-organizing process of the developing brain by regulating the Rho-associated pathway. These data suggest that Rho GTPase pathway might be an alternative target of therapy for patients with GNAO1-associated encephalopathy.

Identifiants

pubmed: 39048611
doi: 10.1038/s41598-024-68062-x
pii: 10.1038/s41598-024-68062-x
doi:

Substances chimiques

GTP-Binding Protein alpha Subunits, Gi-Go EC 3.6.5.1
GNAO1 protein, human 0
rho GTP-Binding Proteins EC 3.6.5.2
rho-Associated Kinases EC 2.7.11.1
Y 27632 138381-45-0
Amides 0
Pyridines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17097

Subventions

Organisme : Japan Society for the Promotion of Science
ID : JP22K15913; JP21K07865; JP23K07334
Organisme : Japan Society for the Promotion of Science
ID : JP22K15913; JP21K07865; JP23K07334
Organisme : Japan Society for the Promotion of Science
ID : JP22K15913; JP21K07865; JP23K07334
Organisme : Japan Society for the Promotion of Science
ID : JP22K15913; JP21K07865; JP23K07334
Organisme : Japan Society for the Promotion of Science
ID : JP22K15913; JP21K07865; JP23K07334
Organisme : Japan Agency for Medical Research and Development
ID : JP20ek0109411; JP23wm0325069
Organisme : Ministry of Health, Labour and Welfare
ID : JP23FC0201; JP21FC1005

Informations de copyright

© 2024. The Author(s).

Références

Kim, S. Y. et al. Spectrum of movement disorders in GNAO1 encephalopathy: In-depth phenotyping and case-by-case analysis. Orphanet. J. Rare Dis. 15, 343. https://doi.org/10.1186/s13023-020-01594-3 (2020).
doi: 10.1186/s13023-020-01594-3 pubmed: 33298085 pmcid: 7724837
Larasati, Y. A. et al. Restoration of the GTPase activity and cellular interactions of Galpha(o) mutants by Zn(2+) in GNAO1 encephalopathy models. Sci. Adv. 8, eabn9350. https://doi.org/10.1126/sciadv.abn9350 (2022).
doi: 10.1126/sciadv.abn9350 pubmed: 36206333 pmcid: 9544338
Nakamura, K. et al. De Novo mutations in GNAO1, encoding a Galphao subunit of heterotrimeric G proteins, cause epileptic encephalopathy. Am. J. Hum. Genet. 93, 496–505. https://doi.org/10.1016/j.ajhg.2013.07.014 (2013).
doi: 10.1016/j.ajhg.2013.07.014 pubmed: 23993195 pmcid: 3769919
Perez-Duenas, B. et al. The genetic landscape of complex childhood-onset hyperkinetic movement disorders. Mov. Disord. 37, 2197–2209. https://doi.org/10.1002/mds.29182 (2022).
doi: 10.1002/mds.29182 pubmed: 36054588 pmcid: 9804670
Saitsu, H. et al. Phenotypic spectrum of GNAO1 variants: Epileptic encephalopathy to involuntary movements with severe developmental delay. Eur. J. Hum. Genet. 24, 129–134. https://doi.org/10.1038/ejhg.2015.92 (2016).
doi: 10.1038/ejhg.2015.92 pubmed: 25966631
Thiel, M. et al. Genotype-phenotype correlation and treatment effects in young patients with GNAO1-associated disorders. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2022-330261 (2023).
doi: 10.1136/jnnp-2022-330261 pubmed: 37225406
Schirinzi, T. et al. Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. Parkinsonism Relat. Disord. 61, 19–25. https://doi.org/10.1016/j.parkreldis.2018.11.019 (2019).
doi: 10.1016/j.parkreldis.2018.11.019 pubmed: 30642806
Hwangpo, A. et al. G protein-regulated inducer of neurite outgrowth (GRIN) modulates sprouty protein repression of mitogen-activated protein kinase (MAPK) activation by growth factor stimulation. J. Biol. Chem. 287, 13674–13685. https://doi.org/10.1074/jbc.M111.320705 (2012).
doi: 10.1074/jbc.M111.320705 pubmed: 22383529 pmcid: 3340172
Ghil, S. H., Kim, B. J., Lee, Y. D. & Suh-Kim, H. Neurite outgrowth-induced by cyclic AMP can be modulated by the α subunit of go. J. Neurochem. 74, 151–158. https://doi.org/10.1046/j.1471-4159.2000.0740151.x (2000).
doi: 10.1046/j.1471-4159.2000.0740151.x pubmed: 10617116
Furutani, Y. & Yoshihara, Y. Proteomic analysis of dendritic filopodia-rich fraction isolated by telencephalin and vitronectin interaction. Front. Synaptic Neurosci. 10, 1–12. https://doi.org/10.3389/fnsyn.2018.00027 (2018).
doi: 10.3389/fnsyn.2018.00027
Nakata, H. & Kozasa, T. Functional characterization of Galphao signaling through G protein-regulated inducer of neurite outgrowth 1. Mol. Pharmacol. 67, 695–702. https://doi.org/10.1124/mol.104.003913 (2005).
doi: 10.1124/mol.104.003913 pubmed: 15585744
Akamine, S. et al. GNAO1 organizes the cytoskeletal remodeling and firing of developing neurons. FASEB J. 34, 16601–16621. https://doi.org/10.1096/fj.202001113R (2020).
doi: 10.1096/fj.202001113R pubmed: 33107105
Parenti, I., Rabaneda, L. G., Schoen, H. & Novarino, G. Neurodevelopmental disorders: From genetics to functional pathways. Trends Neurosci. 43, 608–621. https://doi.org/10.1016/j.tins.2020.05.004 (2020).
doi: 10.1016/j.tins.2020.05.004 pubmed: 32507511
Fujita, Y. & Yamashita, T. Axon growth inhibition by RhoA/ROCK in the central nervous system. Front. Neurosci. 8, 338. https://doi.org/10.3389/fnins.2014.00338 (2014).
doi: 10.3389/fnins.2014.00338 pubmed: 25374504 pmcid: 4205828
Murakoshi, H., Wang, H. & Yasuda, R. Local, persistent activation of Rho GTPases during plasticity of single dendritic spines. Nature 472, 100–104. https://doi.org/10.1038/nature09823 (2011).
doi: 10.1038/nature09823 pubmed: 21423166 pmcid: 3105377
Shen, S. et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc. Natl. Acad. Sci. U S A 111, E5593-5601. https://doi.org/10.1073/pnas.1419161111 (2014).
doi: 10.1073/pnas.1419161111 pubmed: 25480548 pmcid: 4280593
Arildsen, N. S. et al. Involvement of chromatin remodeling genes and the Rho GTPases RhoB and CDC42 in ovarian clear cell carcinoma. Front. Oncol. 7, 109. https://doi.org/10.3389/fonc.2017.00109 (2017).
doi: 10.3389/fonc.2017.00109 pubmed: 28611940 pmcid: 5447048
Govek, E. E., Newey, S. E. & Van Aelst, L. The role of the Rho GTPases in neuronal development. Genes Dev. 19, 1–49. https://doi.org/10.1101/gad.1256405 (2005).
doi: 10.1101/gad.1256405 pubmed: 15630019
Magalhaes, Y. T., Farias, J. O., Silva, L. E. & Forti, F. L. 2021 GTPases, genome, actin: A hidden story in DNA damage response and repair mechanisms. DNA repair 100, 103070. https://doi.org/10.1016/j.dnarep.2021.103070 (2021).
doi: 10.1016/j.dnarep.2021.103070 pubmed: 33618126
Balachandra, S., Sarkar, S. & Amodeo, A. A. The nuclear-to-Cytoplasmic ratio: Coupling DNA content to cell size, cell cycle, and biosynthetic capacity. Ann. Rev. Genet. 56, 165–185. https://doi.org/10.1146/annurev-genet-080320-030537 (2022).
doi: 10.1146/annurev-genet-080320-030537 pubmed: 35977407
Cantwell, H. & Nurse, P. Unravelling nuclear size control. Curr. Genet. 65, 1281–1285. https://doi.org/10.1007/s00294-019-00999-3 (2019).
doi: 10.1007/s00294-019-00999-3 pubmed: 31147736 pmcid: 6820586
Hall, A. & Lalli, G. Rho and Ras GTPases in axon growth, guidance, and branching. Cold Spring Harb. Perspect Biol. 2, a001818. https://doi.org/10.1101/cshperspect.a001818 (2010).
doi: 10.1101/cshperspect.a001818 pubmed: 20182621 pmcid: 2828272
Bagley, J. A., Reumann, D., Bian, S., Levi-Strauss, J. & Knoblich, J. A. Fused cerebral organoids model interactions between brain regions. Nat. Methods 14, 743–751. https://doi.org/10.1038/nmeth.4304 (2017).
doi: 10.1038/nmeth.4304 pubmed: 28504681 pmcid: 5540177
Hanashima, C., Fernandes, M., Hebert, J. M. & Fishell, G. The role of and dorsal midline signaling in the generation of cajal-retzius subtypes. J. Neurosci. 27, 11103–11111. https://doi.org/10.1523/Jneurosci.1066-07.2007 (2007).
doi: 10.1523/Jneurosci.1066-07.2007 pubmed: 17928452 pmcid: 6672859
Hou, P. S., HAilín, D. O., Vogel, T. & Hanashima, C. Transcription and beyond: Delineating FOXG1 function in cortical development and disorders. Front. Cell. Neurosci. 14, 35. https://doi.org/10.3389/fncel.2020.00035 (2020).
doi: 10.3389/fncel.2020.00035 pubmed: 32158381 pmcid: 7052011
Kumamoto, T. & Hanashima, C. Evolutionary conservation and conversion of Foxg1 function in brain development. Dev. Growth. Differ 59, 258–269. https://doi.org/10.1111/dgd.12367 (2017).
doi: 10.1111/dgd.12367 pubmed: 28581027
Kumamoto, T. et al. Foxg1 coordinates the switch from nonradially to radially migrating glutamatergic subtypes in the neocortex through spatiotemporal repression. Cell Rep. 3, 931–945. https://doi.org/10.1016/j.celrep.2013.02.023 (2013).
doi: 10.1016/j.celrep.2013.02.023 pubmed: 23523356 pmcid: 3648982
Li, C. et al. Single-cell brain organoid screening identifies developmental defects in autism. Nature 621, 373–380. https://doi.org/10.1038/s41586-023-06473-y (2023).
doi: 10.1038/s41586-023-06473-y pubmed: 37704762 pmcid: 10499611
Mariani, J. et al. FOXG1-dependent dysregulation of GABA/Glutamate neuron differentiation in autism spectrum disorders. Cell 162, 375–390. https://doi.org/10.1016/j.cell.2015.06.034 (2015).
doi: 10.1016/j.cell.2015.06.034 pubmed: 26186191 pmcid: 4519016
Toma, K., Kumamoto, T. & Hanashima, C. The timing of upper-layer neurogenesis is conferred by sequential derepression and negative feedback from deep-layer neurons. J. Neurosci. 34, 13259–13276. https://doi.org/10.1523/Jneurosci.2334-14.2014 (2014).
doi: 10.1523/Jneurosci.2334-14.2014 pubmed: 25253869 pmcid: 6608336
Sakaguchi, H. et al. Self-organized synchronous calcium transients in a cultured human neural network derived from cerebral organoids. Stem Cell Rep. 13, 458–473. https://doi.org/10.1016/j.stemcr.2019.05.029 (2019).
doi: 10.1016/j.stemcr.2019.05.029
Azzarelli, R., Kerloch, T. & Pacary, E. Regulation of cerebral cortex development by Rho GTPases: Insights from in vivo studies. Front. Cell Neurosci. 8, 445. https://doi.org/10.3389/fncel.2014.00445 (2014).
doi: 10.3389/fncel.2014.00445 pubmed: 25610373
Benedetti, M. C. et al. Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties. Heliyon 10, e26656. https://doi.org/10.1016/j.heliyon.2024.e26656 (2024).
doi: 10.1016/j.heliyon.2024.e26656 pubmed: 38434323 pmcid: 10907651
Bar-Sagi, D. & Hall, A. Ras and Rho GTPases: A family reunion. Cell 103, 227–238. https://doi.org/10.1016/s0092-8674(00)00115-x (2000).
doi: 10.1016/s0092-8674(00)00115-x pubmed: 11057896
Stankiewicz, T. R. & Linseman, D. A. Rho family GTPases: Key players in neuronal development, neuronal survival, and neurodegeneration. Front. Cell. Neurosci. 8, 314. https://doi.org/10.3389/fncel.2014.00314 (2014).
doi: 10.3389/fncel.2014.00314 pubmed: 25339865 pmcid: 4187614
Tolias, K. F., Duman, J. G. & Um, K. Control of synapse development and plasticity by Rho GTPase regulatory proteins. Prog. Neurobiol. 94, 133–148. https://doi.org/10.1016/j.pneurobio.2011.04.011 (2011).
doi: 10.1016/j.pneurobio.2011.04.011 pubmed: 21530608 pmcid: 3129138
Bishop, A. L. & Hall, A. Rho GTPases and their effector proteins. Biochem. J. 348(Pt 2), 241–255 (2000).
doi: 10.1042/bj3480241 pubmed: 10816416 pmcid: 1221060
Sekiguchi, M. et al. ARHGAP10, which encodes Rho GTPase-activating protein 10, is a novel gene for schizophrenia risk. Transl. Psychiatry 10, 247. https://doi.org/10.1038/s41398-020-00917-z (2020).
doi: 10.1038/s41398-020-00917-z pubmed: 32699248 pmcid: 7376022
Takase, S. et al. Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia. Eur J Pharmacol 931, 175207. https://doi.org/10.1016/j.ejphar.2022.175207 (2022).
doi: 10.1016/j.ejphar.2022.175207 pubmed: 35987254
Tanaka, R. et al. Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene. Pharmacol. Res. 187, 106589. https://doi.org/10.1016/j.phrs.2022.106589 (2023).
doi: 10.1016/j.phrs.2022.106589 pubmed: 36462727
Wang, Z., Ren, D. & Zheng, P. The role of Rho/ROCK in epileptic seizure-related neuronal damage. Metab. Brain Dis. 37, 881–887. https://doi.org/10.1007/s11011-022-00909-6 (2022).
doi: 10.1007/s11011-022-00909-6 pubmed: 35119588 pmcid: 9042975
Belal, H. et al. De novo variants in RHOBTB2, an atypical Rho GTPase gene, cause epileptic encephalopathy. Hum. Mutat. 39, 1070–1075. https://doi.org/10.1002/humu.23550 (2018).
doi: 10.1002/humu.23550 pubmed: 29768694
Straub, J. et al. Missense variants in RHOBTB2 cause a developmental and epileptic encephalopathy in humans, and altered levels cause neurological defects in drosophila. Am. J. Hum. Genet. 102, 44–57. https://doi.org/10.1016/j.ajhg.2017.11.008 (2018).
doi: 10.1016/j.ajhg.2017.11.008 pubmed: 29276004
Nakashima, M. et al. De novo variants in CUL3 are associated with global developmental delays with or without infantile spasms. J. Hum. Genet. 65, 727–734. https://doi.org/10.1038/s10038-020-0758-2 (2020).
doi: 10.1038/s10038-020-0758-2 pubmed: 32341456
Danti, F. R. et al. GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome. Neurol. Genet. 3, e143. https://doi.org/10.1212/NXG.0000000000000143 (2017).
doi: 10.1212/NXG.0000000000000143 pubmed: 28357411 pmcid: 5362187
Kelly, M. et al. Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region. Epilepsia 60, 406–418. https://doi.org/10.1111/epi.14653 (2019).
doi: 10.1111/epi.14653 pubmed: 30682224 pmcid: 6452443
Feng, H., Khalil, S., Neubig, R. R. & Sidiropoulos, C. A mechanistic review on GNAO1-associated movement disorder. Neurobiol. Dis. 116, 131–141. https://doi.org/10.1016/j.nbd.2018.05.005 (2018).
doi: 10.1016/j.nbd.2018.05.005 pubmed: 29758257
Feng, H. et al. Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations. Neurology 89, 762–770. https://doi.org/10.1212/WNL.0000000000004262 (2017).
doi: 10.1212/WNL.0000000000004262 pubmed: 28747448 pmcid: 5580866
Menke, L. A. et al. Recurrent GNAO1 mutations associated with developmental delay and a movement disorder. J. Child Neurol. 31, 1598–1601. https://doi.org/10.1177/0883073816666474 (2016).
doi: 10.1177/0883073816666474 pubmed: 27625011
Schirinzi, T. et al. Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. Parkinsonism Relat. Disord. 61, 19–25. https://doi.org/10.1016/j.parkreldis.2018.11.019 (2019).
doi: 10.1016/j.parkreldis.2018.11.019 pubmed: 30642806
Vasconcellos, L. F., Soares, V. P. & de Ricchezza, L. L. Dystonic cerebral palsy phenotype due to GNAO1 variant responsive to levodopa. Tremor Other Hyperkinet. Mov. (N Y) https://doi.org/10.5334/tohm.746 (2023).
doi: 10.5334/tohm.746 pubmed: 37034444
Song, L. et al. Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia. Blood 137, 1181–1191. https://doi.org/10.1182/blood.2020005622 (2021).
doi: 10.1182/blood.2020005622 pubmed: 32898863
Rozic, G., Lupowitz, Z., Piontkewitz, Y. & Zisapel, N. Dynamic changes in neurexins’ alternative splicing: Role of Rho-associated protein kinases and relevance to memory formation. PLoS One 6, e18579. https://doi.org/10.1371/journal.pone.0018579 (2011).
doi: 10.1371/journal.pone.0018579 pubmed: 21533271 pmcid: 3075264
Eiraku, M. et al. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 3, 519–532. https://doi.org/10.1016/j.stem.2008.09.002 (2008).
doi: 10.1016/j.stem.2008.09.002 pubmed: 18983967
Pasca, S. P. et al. A nomenclature consensus for nervous system organoids and assembloids. Nature 609, 907–910. https://doi.org/10.1038/s41586-022-05219-6 (2022).
doi: 10.1038/s41586-022-05219-6 pubmed: 36171373 pmcid: 10571504
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140. https://doi.org/10.1093/bioinformatics/btp616 (2010).
doi: 10.1093/bioinformatics/btp616 pubmed: 19910308
Langhammer, C. G. et al. Automated Sholl analysis of digitized neuronal morphology at multiple scales: Whole cell Sholl analysis versus Sholl analysis of arbor subregions. Cytometry A 77, 1160–1168. https://doi.org/10.1002/cyto.a.20954 (2010).
doi: 10.1002/cyto.a.20954 pubmed: 20687200 pmcid: 4619108
Szabo, M. et al. The kynurenic acid analog SZR104 induces cytomorphological changes associated with the anti-inflammatory phenotype in cultured microglia. Sci Rep 13, 11328. https://doi.org/10.1038/s41598-023-38107-8 (2023).
doi: 10.1038/s41598-023-38107-8 pubmed: 37443330 pmcid: 10344911
Wu, T. et al. clusterProfiler: A universal enrichment tool for interpreting omics data. Innov. (Camb) 2, 100141. https://doi.org/10.1016/j.xinn.2021.100141 (2021).
doi: 10.1016/j.xinn.2021.100141

Auteurs

Ryoji Taira (R)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.
Department of Pediatric Neurology, Fukuoka Children's Hospital, Fukuoka, Japan.

Satoshi Akamine (S)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.

Sayaka Okuzono (S)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.

Fumihiko Fujii (F)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.

Eriko Hatai (E)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.

Kousuke Yonemoto (K)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.

Ryuichi Takemoto (R)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.

Hiroki Kato (H)

Department of Molecular Cell Biology and Oral Anatomy, Graduate School of Dental Science, Kyushu University, Fukuoka, Japan.

Keiji Masuda (K)

Section of Oral Medicine for Children, Division of Oral Health, Growth and Development, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.

Takahiro A Kato (TA)

Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Ryutaro Kira (R)

Department of Pediatric Neurology, Fukuoka Children's Hospital, Fukuoka, Japan.

Keita Tsujimura (K)

Group of Brain Function and Development, Neuroscience Institute of the Graduate School of Science, Nagoya University, Aichi, Japan.
Research Unit for Developmental Disorders, Institute for Advanced Research, Nagoya University, Nagoya, Japan.
Shionogi Pharma Co., Ltd., Settsu, Osaka, Japan.

Kenichiro Yamamura (K)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.

Norio Ozaki (N)

Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Shouichi Ohga (S)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan.

Yasunari Sakai (Y)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Highashi-ku, Fukuoka, 812-8582, Japan. sakai.yasunari.530@m.kyushu-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH